Disparities in delays and outcomes in patients with HER2-positive breast cancer [0.03%]
HER2阳性乳腺癌患者的延迟和预后差异
Margaux Wooster,David DeStephano,Melissa Beauchemin et al.
Margaux Wooster et al.
Purpose: Neoadjuvant chemotherapy (NACT) is often the preferred systemic treatment modality for advanced breast tumors. Delays in NACT initiation are associated with worse outcomes although it is unclear which patients ar...
The association of contemporary mortgage lending bias and receipt of guideline-concordant systemic treatment among older women with breast cancer [0.03%]
当代抵押贷款偏向与乳腺癌老年女性治疗指南相符的系统治疗接受情况的相关性研究
Tina W F Yen,Bethany Canales,Emily L McGinley et al.
Tina W F Yen et al.
Purpose: Structural racism may be associated with disparities in breast cancer access to care and outcomes. We examined the association between contemporary mortgage lending bias (redlining) and the receipt of guideline-c...
Exploring the effect of Duffy status on patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors [0.03%]
探讨杜飞状态对接受细胞周期素依赖性激酶4/6抑制剂治疗的乳腺癌患者的影响
Grace M Ferri,Corina Beiner Martinez,Jose Acevedo et al.
Grace M Ferri et al.
Purpose: To improve clinical decision-making in patients with breast cancer receiving CDK 4/6 inhibitors, we examined Duffy status and relative medication modification at Boston Medical Center. ...
Efficacy and safety of abemaciclib plus endocrine therapy versus endocrine therapy alone in HR + and HER2-negative breast cancer; a systematic review and meta-analysis [0.03%]
阿贝西利联合内分泌治疗与单纯内分泌治疗治疗HR阳性及HER2阴性乳腺癌的疗效和安全性：系统评价和 Meta 分析
Khudija Sadia,Tazmeen Talia,Ishtiaq Hussain et al.
Khudija Sadia et al.
Purpose: Breast cancer is the most commonly diagnosed cancer worldwide. To evaluate the safety and efficacy of abemaciclib in combination with endocrine therapy (ET) for the treatment of Hormone Receptor/ Human Epidermal ...
Risk factors for postoperative bleeding following breast cancer surgery: a systematic review and meta-analysis [0.03%]
乳腺癌术后出血的危险因素：系统评价和荟萃分析
Zhi Yang,Mei Qing,Yina Zhang et al.
Zhi Yang et al.
Objective: Surgical operation serves as a primary approach for addressing cancer of the breast, but it also has potential complications, including hemorrhaging following surgery. Identifying the risk variables associated ...
Megan R Greenberg,Alexandra Noveihed,Mridula George
Megan R Greenberg
Introduction: Breast cancer remains the most frequently diagnosed malignancy among women worldwide. Advances in treatment with the approval of multiple novel therapeutics have led to significant improvements in long-term ...
Assessing endocrine resistance: monitoring circulating ESR1 mutations in Irosustat-treated ER positive breast cancer [0.03%]
评估内分泌耐药性：在Irosustat治疗的雌激素受体阳性乳腺癌中监测循环ESR1突变
Karen Page,Luke J Martinson,Robert K Hastings et al.
Karen Page et al.
Purpose: We aimed to investigate the prevalence and spectrum of ESR1 mutations alongside cell-free DNA (cfDNA) dynamics in patients with estrogen receptor-positive metastatic breast cancer recruited to the phase II IRIS s...
Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study [0.03%]
Sacituzumab govitecan治疗转移性派拉格氏乳癌的疗效和安全性：来自CEBCC-102研究的多国病例系列回顾分析
Justyna Żubrowska,Małgorzata Pieniążek,Anna Polakiewicz-Gilowska et al.
Justyna Żubrowska et al.
Background: Metastatic metaplastic triple-negative breast cancer (mMpTNBC) is a rare, aggressive subtype with poor responsiveness to standard therapies. Sacituzumab govitecan (SG) is effective in metastatic TNBC (mTNBC), ...
Multicenter Study
Breast cancer research and treatment. 2025 Dec 9;215(1):35. DOI:10.1007/s10549-025-07875-4 2025
Prospective validation of the prognostic and predictive impact of uPA/PAI-1 in early breast cancer [0.03%]
uPA/PAI-1对早期乳腺癌预后和预测影响的前瞻性验证
Vanessa Wieder,Julia Engel,Kathleen Eichstädt et al.
Vanessa Wieder et al.
Introduction: An emerging challenge in early breast cancer (eBC) is improving risk assessment through the use of biomarkers. Clinical guidelines have recommended urokinase-type plasminogen activator (uPA) and its inhibito...
The impact of adjuvant chemotherapy on overall survival in premenopausal (age ≤ 50 years) hormone and node positive breast cancer patients with an Oncotype Dx score of 25 or less. A NCDB analysis [0.03%]
基于NCDB数据库分析的OncoType DX低风险（分数≤25分）阳性淋巴结和激素受体阳性的绝经前乳腺癌患者辅助化疗对总生存的影响
Prashanth Ashok Kumar,Ghanshyam Ghelani,Gowthami Koorapati et al.
Prashanth Ashok Kumar et al.
Purpose: The RxPONDER trial showed improved outcomes in premenopausal hormone positive breast cancer (BC) with 1-3 nodes and OncotypeDx (RS) score ≤ 25 with adjuvant chemotherapy (Chemo) use. This study aims to determine...